[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353576-105":59,"doc-detail-353576-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cilp2-from-ecm-component-to-a-pleiotropic-modulator-in-metabolic-dysfunction-cancer-and-beyond-review","CILP2 - From ECM Component to a Pleiotropic Modulator in Metabolic Dysfunction, Cancer, and Beyond - Review","","Initially characterized as a component of the extracellular matrix (ECM) in cartilage, cartilage intermediate layer protein 2 (CILP2) is recognized as a pleiotropic secretory protein with roles spanning physiology and disease. This review integrates evidence positioning CILP2 at the intersection of metabolic dysfunction, cancer, and other pathologies. Genomic data identify the NCAN-CILP2 locus as a hotspot affecting dyslipidemia and cardiovascular risk. Functional studies show metabolic stress induces CILP2 and contributes to dyslipidemia, diabetes, sarcopenia, fibrosis, and neurodevelopment, while oncology evidence links CILP2 to tumor proliferation, metastasis, Akt/EMT signaling, and immune infiltration. Serum dysregulation supports biomarker potential and therapeutic targeting.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cilp2-from-ecm-component-to-a-pleiotropic-modulator-in-metabolic-dysfunction-cancer-and-beyond-review/353576/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cilp2-from-ecm-component-to-a-pleiotropic-modulator-in-metabolic-dysfunction-cancer-and-beyond-review/353576.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is CILP2 and how did its role evolve from the ECM?","Question",{"text":112,"@type":113},"CILP2 was initially described as a cartilage extracellular matrix component, but it is now recognized as a pleiotropic secretory protein. The review summarizes how evidence supports its function as a multifunctional signaling modulator beyond structural roles.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does metabolic stress affect CILP2 and related diseases?",{"text":117,"@type":113},"CILP2 is upregulated by metabolic stressors such as high glucose and oxidatively modified LDL. The review links this to impairments in glucose metabolism and mitochondrial function, contributing to dyslipidemia, diabetes, and sarcopenia.",{"name":119,"@type":110,"acceptedAnswer":120},"What roles does CILP2 play in cancer progression?",{"text":121,"@type":113},"CILP2 is overexpressed in multiple cancers and correlates with poor prognosis. The review reports effects on tumor proliferation and metastasis, involving Akt/EMT signaling and remodeling of the tumor microenvironment, including immune infiltration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353576,1790563950,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Review  \nCILP2: From ECM Component to a Pleiotropic Modulator in Metabolic Dysfunction, Cancer, and Beyond  \nZheqiong Tan *, Suotian Liu and Zhongxin Lu *  \nAcademic Editors: Khaled A. Elsaid and Davide Vigetti  \nReceived: 10 December 2025  \nRevised: 14 January 2026  \nAccepted: 17 January 2026  \nPublished: 19 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDepartment of Medical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China; [2021110549@stu.cqmu.edu.cn](2021110549@stu.cqmu.edu.cn)  \n* Correspondence: [tanzheqiong@zxhospital.com](tanzheqiong@zxhospital.com) (Z.T.); [luzhongxin@zxhospital.com](luzhongxin@zxhospital.com) (Z.L.)  \nAbstract  \nInitially characterized as a component of the extracellular matrix (ECM) in cartilage, cartilage intermediate layer protein 2 (CILP2) is now recognized as a pleiotropic secretory protein with far-reaching roles in physiology and disease. This review synthesizes evidence establishing CILP2 as a key modulator at the nexus of metabolic dysfunction, cancer, and other pathologies. Genomic studies have firmly established the NCAN-CILP2 locus as a hotspot for genetic variants influencing dyslipidemia and cardiovascular risk. Functionally, CILP2 is upregulated by metabolic stress, including high glucose and oxidatively modified LDL (oxLDL), and actively contributes to pathologies such as dyslipidemia, diabetes, and sarcopenia by impairing glucose metabolism and mitochondrial function. Its role extends to fibrosis and neurodevelopment, promoting hypertrophic scar formation and neurogenesis through interactions with ATP citrate lyase (ACLY) and Wnt3a, respectively. More recently, CILP2 has emerged as an oncoprotein, overexpressed in multiple cancers, including pancreatic ductal adenocarcinoma and colorectal cancer. It drives tumor proliferation and metastasis and correlates with tumor microenvironment remodeling through mechanisms involving Akt/EMT signaling and immune infiltration. The dysregulation of CILP2 in patient serum and its correlation with disease severity and poor prognosis highlight it as a promising biomarker and a compelling therapeutic target across a spectrum of human diseases.  \nKeywords: CILP2; extracellular matrix; metabolic syndrome; cancer; biomarker  \n1. Introduction  \nThe extracellular matrix (ECM) is not merely a static scaffold for cellular attachment but also a dynamic and bioactive entity that critically regulates tissue homeostasis, cell signaling, and disease pathogenesis [1] . In cancer, the ECM undergoes profound remodeling, becoming dysregulated in its density and composition, which in turn shapes a tumorpermissive microenvironment that fosters growth, invasion, and therapeutic resistance [2] . This has spurred growing interest in targeting the ECM for novel therapeutic strategies.  \nAmong the myriad components of the ECM, the cartilage intermediate layer proteins (CILPs) have emerged as molecules of increasing significance. The CILP family comprises two highly homologous secretory glycoproteins: CILP1 and CILP2 [3] . CILP1 was first identified in 1998 and named for its deposition in the intermediate zone of articular cartilage [4] . CILP2, a homologue to CILP1, was first discovered in mouse cartilage by means of transcriptomics. The cDNAs of CILP1 and CILP2 are 51.5% identical, and the proteins of CILP1 and CILP2 are 66% conserved on an amino acid basis [5] . Compared to CILP1, CILP2  \nappears to be more abundant in the deeper middle region of the articular cartilage, associated with the maintenance of joint stability [6] . However, its expression is not confined to cartilage; it is also expressed in muscle, heart, brain, skin, and tumor tissues, hinting at broader physiological and pathological functions [7] . As ","cbCaidSVsq1yB8JI","https://ap.wps.com/l/cbCaidSVsq1yB8JI","pdf",1767753,"English","# 1. Introduction\n# 2. Structure of CILP2\n# Abstract\n# Keywords","[{\"question\":\"What is CILP2 and how did its role evolve from the ECM?\",\"answer\":\"CILP2 was initially described as a cartilage extracellular matrix component, but it is now recognized as a pleiotropic secretory protein. The review summarizes how evidence supports its function as a multifunctional signaling modulator beyond structural roles.\"},{\"question\":\"How does metabolic stress affect CILP2 and related diseases?\",\"answer\":\"CILP2 is upregulated by metabolic stressors such as high glucose and oxidatively modified LDL. The review links this to impairments in glucose metabolism and mitochondrial function, contributing to dyslipidemia, diabetes, and sarcopenia.\"},{\"question\":\"What roles does CILP2 play in cancer progression?\",\"answer\":\"CILP2 is overexpressed in multiple cancers and correlates with poor prognosis. The review reports effects on tumor proliferation and metastasis, involving Akt/EMT signaling and remodeling of the tumor microenvironment, including immune infiltration.\"}]","CILP2 - From ECM Component to a Pleiotropic Modulator in Metabolic Dysfunction, Cancer, and Beyond - Review | PDF",1790106109,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81c86cb3e92eddbc0feecf5b1530f135.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dca74a0b2e87a8ca020fbfa60a0fc916.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99d81b217a9b75a79ecf70b7a48f323f.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bf30ab2b32266eb9194547ff4c194c3.webp",980,692]